Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 2-3 trial of two postoperative reirradiation modalities in previously irradiated head and neck cancer
2009-017047-34Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Dec 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab, fluorouracil and hydroxyurea in head and neck cancer (HNC) (2 arms), sponsored by Gustave Roussy. Primary endpoints: Acute toxicity and Recurrence-free survival. Started Dec 2009; status: active.
02
Drugs
cetuximabfluorouracilhydroxyurea
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on 2009-017047-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017047-34.